Since starting Cosentyx, many patients have reported improvements in their condition. Cosentyx, also known as secukinumab, is a biologic medication used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
According to the official Cosentyx website, clinical studies have shown that a significant number of patients experienced improvements in their symptoms after starting treatment with Cosentyx. For example, in a study of patients with psoriasis, 9 out of 10 patients achieved clear or almost clear skin after 16 weeks of treatment with Cosentyx. Similarly, in a study of patients with psoriatic arthritis, Cosentyx was found to significantly reduce joint pain and swelling, and improve physical function.
Furthermore, a study published in the Journal of Rheumatology [3] evaluated the efficacy of Cosentyx in patients with ankylosing spondylitis. The study found that Cosentyx led to significant improvements in disease activity, physical function, and quality of life. Additionally, a study published in the Journal of Dermatological Treatment [2] demonstrated the effectiveness of Cosentyx in treating moderate to severe plaque psoriasis.
It is important to note that individual responses to Cosentyx may vary, and not all patients will experience the same level of improvement. It is recommended to consult with a healthcare professional to determine if Cosentyx is the right treatment option for you and to monitor your progress.
In conclusion, based on the information provided, there have been noticeable improvements in patients' conditions since starting Cosentyx. Clinical studies and research have shown that Cosentyx can effectively improve symptoms and quality of life in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Sources:
[2] Kimball AB, et al. Long-term efficacy of secukinumab in patients with moderate-to-severe plaque psoriasis: 5-year results from a phase 3b extension study. Journal of Dermatological Treatment. 2019; 30(4): 341-350.
[3] Baraliakos X, et al. Secukinumab in patients with ankylosing spondylitis: a long-term, open-label extension study. Journal of Rheumatology. 2018; 45(2): 195-204.
[4] Cosentyx. Frequently Asked Questions. Retrieved from https://www.cosentyx.com/ankylosing-spondylitis/faq
[5] Drug Patent Watch. Cosentyx - Tradename Details. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[6] Mease PJ, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 2 study. ACR Open Rheumatology. 2020; 2(1): 18-25.